Gemini Therapeutics announced that Marc E. Uknis MD, FACS has been appointed to serve as Chief Medical Officer, effective May 7, 2020. Dr. Uknis brings more than 35 years of experience in industry and academia in research programs across various areas including surgery, rare disease, immunology, genetics and infectious disease, and will lead Gemini’s clinical development activities. Prior to Gemini, Dr. Uknis joined Achillion in 2018 as the Vice President and global Nephrology development lead for complement factor D inhibition programs, which was acquired recently by Alexion.